These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17607321)

  • 1. Peptide mimotopes selected with HIV-1-blocking monoclonal antibodies against CCR5 represent motifs specific for HIV-1 entry.
    Königs C; Pustowka A; Irving J; Kessel C; Klich K; Wegner V; Rowley MJ; Mackay IR; Kreuz W; Griesinger C; Dietrich U
    Immunol Cell Biol; 2007 Oct; 85(7):511-7. PubMed ID: 17607321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody screening of a phage-displayed random peptide library reveals mimotopes of chemokine receptor CCR5: implications for the tertiary structure of the receptor and for an N-terminal binding site for HIV-1 gp120.
    Königs C; Rowley MJ; Thompson P; Myers MA; Scealy M; Davies JM; Wu L; Dietrich U; Mackay CR; Mackay IR
    Eur J Immunol; 2000 Apr; 30(4):1162-71. PubMed ID: 10760806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
    Olson WC; Rabut GE; Nagashima KA; Tran DN; Anselma DJ; Monard SP; Segal JP; Thompson DA; Kajumo F; Guo Y; Moore JP; Maddon PJ; Dragic T
    J Virol; 1999 May; 73(5):4145-55. PubMed ID: 10196311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.
    Lee B; Sharron M; Blanpain C; Doranz BJ; Vakili J; Setoh P; Berg E; Liu G; Guy HR; Durell SR; Parmentier M; Chang CN; Price K; Tsang M; Doms RW
    J Biol Chem; 1999 Apr; 274(14):9617-26. PubMed ID: 10092648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
    Xiang SH; Farzan M; Si Z; Madani N; Wang L; Rosenberg E; Robinson J; Sodroski J
    J Virol; 2005 May; 79(10):6068-77. PubMed ID: 15857992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement of multiple phage displayed peptide libraries for optimal mapping of a conformational antibody epitope on CCR5.
    O'Connor KH; Königs C; Rowley MJ; Irving JA; Wijeyewickrema LC; Pustowka A; Dietrich U; Mackay IR
    J Immunol Methods; 2005 Apr; 299(1-2):21-35. PubMed ID: 15914189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.
    Siciliano SJ; Kuhmann SE; Weng Y; Madani N; Springer MS; Lineberger JE; Danzeisen R; Miller MD; Kavanaugh MP; DeMartino JA; Kabat D
    J Biol Chem; 1999 Jan; 274(4):1905-13. PubMed ID: 9890944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S; Kennedy M; King LR; Golding H
    J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens.
    Pastori C; Clivio A; Diomede L; Consonni R; De Mori GM; Longhi R; Colombo G; Lopalco L
    J Virol; 2008 Apr; 82(8):4125-34. PubMed ID: 18256149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins.
    Hill CM; Kwon D; Jones M; Davis CB; Marmon S; Daugherty BL; DeMartino JA; Springer MS; Unutmaz D; Littman DR
    Virology; 1998 Sep; 248(2):357-71. PubMed ID: 9721244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of the extracellular domains of C-C chemokine receptor 5 and the in vitro effects on simian immunodeficiency virus or HIV infectivity.
    Lehner T; Doyle C; Wang Y; Babaahmady K; Whittall T; Tao L; Bergmeier L; Kelly C
    J Immunol; 2001 Jun; 166(12):7446-55. PubMed ID: 11390497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor.
    Chain BM; Noursadeghi M; Gardener M; Tsang J; Wright E
    Vaccine; 2008 Oct; 26(45):5752-9. PubMed ID: 18765264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.
    Zhang J; Rao E; Dioszegi M; Kondru R; DeRosier A; Chan E; Schwoerer S; Cammack N; Brandt M; Sankuratri S; Ji C
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1386-97. PubMed ID: 17242138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
    Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
    J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
    Misumi S; Nakajima R; Takamune N; Shoji S
    J Virol; 2001 Dec; 75(23):11614-20. PubMed ID: 11689643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.